SCHEMBL11960320

SCHEMBL11960320

CC(C)c1cc(N2CCC(O)CC2)ncn1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 3/20 0.45
▸ ITGB2 P05107 4/20 0.44
▸ ICAM1 P05362 4/20 0.44
▸ ITGAL P20701 4/20 0.44
▸ SMO Q99835 1/20 0.40
▸ GPR119 Q8TDV5 1/20 0.40
▸ HRH4 Q9H3N8 4/20 0.40
▸ HRH3 Q9Y5N1 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ KRAS P01116 1/20 0.35
▸ SOS1 Q07889 1/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ TYK2 P29597 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14868472 0.91 ITGB2 (0.45) LRRK2ITGB2ICAM1ITGALGPR119
SCHEMBL14868421 0.91 ITGB2 (0.45) LRRK2ITGB2ICAM1ITGALGPR119
SCHEMBL14868458 0.91 ITGB2 (0.45) LRRK2ITGB2ICAM1ITGALGPR119
SCHEMBL11960334 0.84 HRH3 (0.42) LRRK2ITGB2ICAM1ITGALHRH4
SCHEMBL11960323 0.82 SMN1; SMN2 (0.46) LRRK2HRH4HRH3CYP2C19
SCHEMBL13034784 0.80 SMN1; SMN2 (0.49) LRRK2HRH4HRH3JAK2CYP2C19
SCHEMBL11981591 0.79 SMO (0.46) LRRK2ITGB2ICAM1ITGALSMO
SCHEMBL11960308 0.79 HRH4 (0.53) HRH4HRH3CYP2C19
SCHEMBL19658497 0.78 MAP4K4 (0.45) ITGB2ICAM1ITGALHRH4HRH3
SCHEMBL10223327 0.78 CYP2C19 (0.58) LRRK2ITGB2ICAM1ITGALHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9309240-B2 Pyrazolopyridine compounds, compositions and methods of use GENENTECH, INC. (US) 2016-04-12 — — US disclosed
US-20140206702-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2014-07-24 — — US disclosed
US-20140171408-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2014-06-19 — — US disclosed
US-20130252941-A1 PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2013-09-26 — — US disclosed
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2013-04-18 — — US disclosed
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 — — US disclosed
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE TYK2, IRAK1, IRAK4 LRRK2 1710/4885ITGB2 1071/4885ICAM1 2591/4885
US-20140206702-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE P2RX6, P2RY6, CYP2D6 LRRK2 4687/4885ITGB2 2638/4885ICAM1 3369/4885
US-20130252941-A1 PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE P2RX5, P2RX4, P2RY1 LRRK2 3622/4885ITGB2 2639/4885ICAM1 4784/4885
US-20140171408-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F12, CHRM1, NPY1R LRRK2 4285/4885ITGB2 860/4885ICAM1 4815/4885
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F12, CHRM1, NPY1R LRRK2 4285/4885ITGB2 860/4885ICAM1 4815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback